Previous 10 | Next 10 |
Shares of Twist Bioscience (NASDAQ: TWST) , a biotech company that makes synthetic DNA-based products, including synthetic genes, antibody libraries for drug development and tools for next-generation sample preparation, jumped 25.1% in July, according to according to data from S&a...
The following slide deck was published by Twist Bioscience Corporation in conjunction with their 2022 Q3 earnings call. For further details see: Twist Bioscience Corporation 2022 Q3 - Results - Earnings Call Presentation
Twist Bioscience press release ( NASDAQ: TWST ): FQ3 GAAP EPS of -$1.08 beats by $0.23 . Revenue of $56.11M (+60.2% Y/Y) beats by $4.05M . FY2022 Outlook : Revenue is now expected to be approximately $203M, an increase from previous guidance of $191M to $19...
-- Record revenue of $56.1M in 3QFY22; Increase of 60% over $35.0M in Fiscal 2021 -- -- Orders increased 53% in 3QFY22 over fiscal 2021 to $59.7M -- -- Increases revenue guidance to $203 million for full year fiscal 2022 -- Twist Bioscience Corporation (NASDAQ: TWST)...
Twist Bioscience ( NASDAQ: TWST ) is scheduled to announce Q2 earnings results on Friday, August 5th, before market open. The consensus EPS Estimate is -$1.31 (-67.9% Y/Y) and the consensus Revenue Estimate is $52.06M (+66.9% Y/Y). Over the last 2 years, TWST has bea...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Steffen Hellmold, senior vice president, business development for data storage, will present at th...
Twist Bioscience ( NASDAQ: TWST ), a developer of synthetic DNA-based products and its partner Biotia, Inc. announced on Tuesday that the FDA authorized their product, SARS-CoV-2 Next-Generation Sequencing Assay for the detection of COVID variants and specific gene mutations. ...
Zone of potential insufficiency, where storage demand outstrips capacity, could be >25 zettabytes during 2030 Approximately 75% of all data stored to be ‘cold’ data, infrequently accessed ‘just in case’ it is needed Data retention times are ‘...
- FDA EUA Variant Calling Assay Allows for Sequencing to Inform Patient Treatment - Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Cathie Wood’s flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ), are up about 20% the past month. Despite the short term recovery, the ETF is still down more than 45% year-...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...